What is the management and cause of Acute Generalized Exanthematous Pustulosis (AGEP)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 31, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management and Cause of Acute Generalized Exanthematous Pustulosis (AGEP)

Cause

AGEP is primarily a drug-induced reaction, with medications responsible for over 90% of cases, most commonly antibiotics including beta-lactams (ampicillin/amoxicillin), quinolones, pristinamycin, anti-infective sulfonamides, terbinafine, (hydroxy)chloroquine, and diltiazem. 1, 2

Pathophysiology

  • The neutrophil attractant chemokine IL-8 drives the inflammatory cascade, with target cell killing occurring via both perforin and FAS-mediated pathways 3
  • Less common triggers include infections, vaccinations, ingestion of various substances, and spider bites 4

Management

Immediate withdrawal of the suspected causative drug is the single most critical intervention, as AGEP is self-limited and typically resolves within 1-2 weeks after drug discontinuation. 1, 2, 5

Initial Assessment

  • Quantify body surface area (BSA) involvement: mild-moderate (10-30% BSA) versus severe (>30% BSA) 6
  • Obtain bacterial cultures before initiating any antimicrobial therapy if secondary infection is suspected 6
  • Document fever, leukocytosis, and any systemic organ involvement 4, 5

Treatment Algorithm by Severity

Mild to Moderate AGEP (10-30% BSA):

  • Apply topical low to moderate potency corticosteroids to affected areas 6, 1
  • Provide gentle skin care with emollients 6
  • Avoid unnecessary antibiotics to prevent further drug exposure 1

Severe AGEP (>30% BSA or systemic symptoms):

  • Administer systemic corticosteroids: prednisone 0.5-1 mg/kg body weight for 7 days, then taper over 4-6 weeks 6
  • Hold immune checkpoint inhibitor therapy if AGEP is immunotherapy-related until resolution to grade 1 6
  • Consider inpatient management for close monitoring 7

Symptomatic Management

  • Prescribe oral antihistamines for severe pruritus 6
  • Consider gabapentin or pregabalin for refractory pruritus 6
  • Administer appropriate antibiotics based on culture sensitivities for at least 14 days if secondary bacterial infection is confirmed 6

Follow-up

  • Reassess after 2 weeks of initial therapy 6
  • Escalate treatment or reconsider diagnosis if no improvement or worsening occurs 6
  • Obtain dermatology consultation for persistent or severe cases 6
  • Arrange allergological work-up after acute phase resolution to identify the causative agent and prevent future exposures 7

Critical Diagnostic Considerations

AGEP must be distinguished from other pustular eruptions, particularly generalized pustular psoriasis, drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), and infectious causes. 8, 4

  • Histopathology reveals spongiform subcorneal and/or intraepidermal pustules with neutrophilic and eosinophilic infiltration and papillary dermal edema 2, 5
  • AGEP typically has rapid onset (within 48 hours of drug exposure) and prompt resolution (within 2 weeks), distinguishing it from pustular psoriasis which has a more chronic course 4, 2

Common Pitfalls

  • Do not empirically start antibiotics without culture confirmation, as this introduces additional potential drug triggers 1
  • Do not confuse AGEP with infectious pustulosis—AGEP pustules are sterile 4, 5
  • While topical and systemic corticosteroids are widely used, strong evidence for their effectiveness is lacking; however, they remain standard practice based on expert consensus 7

References

Research

Acute Generalised Exanthematous Pustulosis: An Update.

Indian journal of dermatology, 2018

Research

[Acute generalized exanthematous pustulosis].

Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2014

Guideline

Acute Generalized Exanthematous Pustulosis (AGEP) Pathogenesis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Acute generalized exanthematous pustulosis (AGEP): A review and update.

Journal of the American Academy of Dermatology, 2015

Guideline

Management of Acute Generalized Exanthematous Pustulosis (AGEP)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Acute generalized exanthematous pustulosis: European expert consensus for diagnosis and management.

Journal of the European Academy of Dermatology and Venereology : JEADV, 2024

Guideline

Differential Diagnosis of Target Skin Lesions

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.